A randomized comparison of novel bioresorbable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with acute coronary syndromes: The CENTURY II high risk ACS substudy

Victor A. Jiménez, Andrés Iñiguez, José A. Baz, Mariano Valdés, Alberto Ortiz, André Vuilliomenet, Vicente Mainar, Dariusz Dudek, Shmuel Banai, David Tüller, Jean Louis Bonnet, Antonio De Miguel, Guillermo Bastos, William Wijns, Shigeru Saito

Research output: Contribution to journalArticlepeer-review

Abstract

Background To investigate clinical outcomes of percutaneous coronary intervention using a sirolimus-eluting stent with bioresorbable polymer, Ultimaster (BP-SES) compared with a permanent polymer everolimus-eluting stent, Xience (PP-EES) in patients with high risk (ST-segment elevation and non-ST-segment elevation myocardial infarction) acute coronary syndromes (ACS) enrolled in the CENTURY II trial. Methods CENTURY II is a prospective, multicenter, randomized, single blind, controlled trial comparing BP-SES and PP-EES, with primary endpoint of target lesion failure (TLF) at 9 month post-stent implantation. Out of 1123 patients enrolled in CENTURY II trial, 264 high risk ACS patients were included in this subgroup analysis, and the clinical outcomes including target lesion failure (TLF), target vessel failure (TVF), cardiac death, myocardial infarction, and stent thrombosis were evaluated at 24 months. Results The baseline clinical, angiographic and procedural characteristics were similar between two groups. At 24 months, TLF occurred in 6.3% of patients receiving a BP-SES and 6.5% of patients receiving a PP-EES (P = 0.95); TVF was 6.3% in patients receiving a BP-SES and 9.4% in patients receiving a PP-EES (P = 0.36). There were no significant differences in cardiac death, myocardial infarction and stent thrombosis rate. Conclusions BP-SES achieved similar safety and efficacy outcomes as PP-EES in this ACS subgroup of CENTURY II study, at 24-month follow-up. This finding is hypothesis-generating and needs to be confirmed in larger trials with longer follow-up.

Original languageEnglish
Pages (from-to)355-361
Number of pages7
JournalCardiovascular Revascularization Medicine
Volume17
Issue number6
DOIs
StatePublished - 1 Sep 2016
Externally publishedYes

Keywords

  • Acute coronary syndrome
  • bioresorbable polymer
  • drug-eluting stent

Fingerprint

Dive into the research topics of 'A randomized comparison of novel bioresorbable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with acute coronary syndromes: The CENTURY II high risk ACS substudy'. Together they form a unique fingerprint.

Cite this